Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7.

Abstract

Downregulation of claudin 1, a critical tight junction protein, has been correlated with increased invasiveness in breast cancer. However, recent studies suggest that claudin 1 contributes to the progression of some molecular subtypes of breast cancer. In this study, claudin 1 promotes migration in luminal-like MCF7 human breast cancer cells and increases their sensitivity to tamoxifen, etoposide, and cisplatin. We also observed an inverse relationship between upregulation of claudin 1 and TGFβ. Collectively, our results suggest that claudin 1 has the potential to be used as a predictive marker for treatment efficacy for specific breast cancer patient subgroups.

• Authors: Bowen Zhou, Anne Blanchard, Nan Wang, Xiuli Ma, Jihyun Han, Ingo Schroedter, Etienne Leygue, Yvonne Myal
• Journal: Cancer investigation (Cancer Invest) Vol. 33 Issue 9 Pg. 429-39 ( 2015) ISSN: 1532-4192 [Electronic] England
• PMID: 26288115 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Claudin-1
• Transforming Growth Factor beta
• Tamoxifen
• Etoposide
• Cisplatin

Topics

• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (drug therapy, genetics)
• Cell Line, Tumor
• Cell Movement (drug effects, genetics)
• Cisplatin (pharmacology)
• Claudin-1 (genetics)
• Down-Regulation (drug effects, genetics)
• Etoposide (pharmacology)
• Female
• Gene Expression (drug effects, genetics)
• Humans
• MCF-7 Cells
• Tamoxifen (pharmacology)
• Tight Junctions (drug effects, genetics)
• Transforming Growth Factor beta (genetics)